Evidence map›Paper›PMID 18834354›Full record

ArticleBasic & clinical pharmacology & toxicology2008

Antipsychotic drugs inhibit the function of breast cancer resistance protein.

Jun-Sheng Wang, Hao-Jie Zhu, John S Markowitz, Jennifer L Donovan, Hong-Jie Yuan, C Lindsay Devane

Open access · bronzeAbstract read
In one paragraph

Article in Basic & clinical pharmacology & toxicology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. PharmGKB summary: clozapine pathway, pharmacokinetics.Pharmacogenetics and genomics · 2018
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jun-Sheng WangLaboratory of Drug Disposition and Pharmacogenetics, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA. junsheng.wang@bms.com
Hao-Jie Zhu
John S Markowitz
Jennifer L Donovan
Hong-Jie Yuan
C Lindsay Devane
Medical University of South Carolina · US

Funding

PGP Regulation of Antipsychotic Exposure and EffectsR01MH071811 · NIMH · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DEVANE, C LINDSAY LINDSAY · 2005 to 2008
$1.1M
NIMH NIH HHS R01 MH071811
6 · The paper itself

Abstract

The ABCG2 transporter breast cancer resistance protein (BCRP) has been identified in several physiological sites. It has been suggested to play an important role in disposition of many drugs and environmental toxins. We investigated the effects of several antipsychotic drugs, including risperidone, 9-hydroxy-risperidone (paliperidone), olanzapine, quetiapine, clozapine, haloperidol and chlorpromazine, and a positive control inhibitor Ko143 on functions of BCRP in MCF7 and BCRP over-expressing MCF7/MX100 cell lines using a BCRP prototypical substrate mitoxantrone. Our findings indicated that the tested antipsychotics rank order of potency of inhibition of BCRP according to concentrations required to reach 50% of maximum inhibition (IC(50)) was as follows: Ko143 (0.07 microM) > risperidone (38.1 microM) > clozapine (42.0 microM) > paliperidone (51 microM) > chlorpromazine (52.2 microM) > quetiapine (66.1 microM) > olanzapine = haloperidol (>100.0 microM). We further tested the effects of various concentrations of risperidone on the BCRP-mediated transport of oestrone-3-sulfate in a colon carcinoma cell line, Caco-2, a widely used model to study drug absorption. Our findings show that risperidone at concentrations ranging from 1 to 100 microM significantly inhibited intracellular accumulation of oestrone-3-sulfate in Caco-2 cell monolayers. The present results suggest that a potential source of pharmacokinetic interactions exists between BCRP substrates and several antipsychotics.

Indexed as

Antipsychotic AgentsATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 2Caco-2 CellsCell Line, TumorDose-Response Relationship, DrugDrug InteractionsEstroneFlow CytometryHumansInactivation, MetabolicMitoxantroneNeoplasm ProteinsSubstrate SpecificityABCG2 protein, humanAntipsychotic AgentsATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 2Estroneestrone sulfateMitoxantroneNeoplasm Proteins

Identifiers

PMID18834354
PMCPMC2637613
OpenAlexW1979902556

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.